Intuitive Surgical, Inc.

NASDAQ Global Select

Articles

62
Show Summary
Show Bulletpoints
Detailed View
Slightly Bullish +25

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Intuitive Surgical, Inc. (ISRG) shares have recently declined by -7.8% over the past month, underperforming both the Zacks S&P 500 composite index, which lost -3.3%, and its respective industry sector, the Medical - Instruments, which saw a decline of -6.4%. While market rumors can cause short-term volatility, the primary determinant for long-term investment decisions remains fundamental factors, specifically earnings projections. Analysts at Zacks Investment Research emphasize that shifts in sell-side earnings estimates correlate strongly with stock price movements, as these revisions influence the calculation of a company's fair value based on its future earning stream. For the current quarter, Intuitive Surgical is projected to report earnings per share (EPS) of $2.08, representing a 14.9% increase year-over-year, while consensus estimates have remained relatively stable with a +0.3% change in the last 30 days. Annual consensus estimates show continued growth, with a forecast of $10.05 EPS for the current fiscal year (a 12.5% increase) and $11.39 EPS for the next fiscal year (a 13.3% increase). Revenue forecasts align with these projections, showing a consensus sales estimate of $2.61 billion for the quarter (+15.8% year-over-year), compared to reported revenues of $2.87 billion last quarter, which beat earnings expectations by +12.44%. The company has demonstrated strong execution, beating consensus EPS estimates for four consecutive trailing quarters and topping revenue estimates three times in that period. Despite this historical outperformance, current valuation metrics suggest Intuitive Surgical trades at a premium relative to peers, reflected in a Zacks Value Style Score of D. Based on its earnings estimate revisions and other factors, the stock currently holds a Zacks Rank #3 (Hold), indicating it may be expected to perform in line with the broader market rather than significantly outperforming or underperforming in the near term.

📉 Shares dropped -7.8% last month, underperforming benchmarks.

💵 Reported revenue matched estimates while EPS beat by +12.44%.

🔮 Zacks Rank #3 suggests stock will move in line with market.

⚙ Full-year earnings projected at $10.05, up 12.5% year over year.

📉 Sales growth projected at +15.8% for current quarter.

📉 Intuitive Surgical shares fell -7.8% over the past month, underperforming both the Zacks S&P 500 (-3.3%) and the Medical Instruments industry (-6.4%).

🎯 Analysts are focusing on changes in future earnings projections as the primary driver of fair stock value rather than short-term news or rumors.

💰 The company expects quarterly earnings of $2.08 per share, representing a +14.9% increase from the same quarter last year.

📈 Full-year fiscal earnings consensus is projected at $10.05 (+12.5% YoY), while next-year estimates are set at $11.39 (+13.3% YoY).

📉 The Zacks Consensus estimate changed slightly over the last month, with a minor -0.2% revision for the next fiscal year.

🌐 Based on earnings estimate revisions and other factors, Intuitive Surgical currently holds a Zacks Rank of #3 (Hold).

💵 Reported revenues of $2.87 billion in the last quarter matched consensus estimates exactly but beat EPS expectations by +12.44%.

⚙️ The company has beaten EPS estimates in each of the trailing four quarters and topped revenue estimates three times during that period.

📉 Sales projections indicate +15.8% growth for the current quarter, +14.8% for the current fiscal year, and +12.2% for next fiscal year.

💰 Valuation analysis places Intuitive Surgical at a premium to peers, earning a D grade on the Zacks Value Style Score system.

🔮 A Zacks Rank #3 suggests the stock may perform in line with the broader market in the near term despite the recent price decline.

Bullish Signals
  • Intuitive Surgical expected to post $2.08 EPS, up 14.9% from prior quarter.
  • Full-year consensus estimate of $10.05 EPS reflects 12.5% year-over-year growth.
  • Next fiscal year earnings guidance of $11.39 shows 13.3% increase.
  • Quarterly sales estimate reaches $2.61B, up 15.8% from prior year.
  • Last quarter revenues hit $2.87B, exceeding estimates with strong EPS surprise.
  • Company has beaten EPS estimates for each of trailing four quarters.
  • Revenue estimates were topped three times over last four-quarter period.
  • Fiscal year revenue up 14.8% and next fiscal year growth 12.2%.
  • Long-term earnings trajectory supported by consistent double-digit growth rates.
Risk Factors
  • Intuitive Surgical shares down 7.8% this month.
  • Stock underperforms S&P 500 and Medical Instruments peers.
  • Zacks Rank #3 suggests in-line performance with market.
  • Graded D on Value Style Score indicating overvaluation.
  • Consensus earnings estimate revised down -0.2% recently.
Bullish Signals
  • Intuitive Surgical is expected to post earnings of $2.08 per share for the current quarter, indicating a change of +14.9% from the year-ago quarter.
  • The consensus earnings estimate of $10.05 for the current fiscal year indicates a year-over-year change of +12.5%, signaling sustained growth prospects.
  • For the next fiscal year, the consensus earnings estimate of $11.39 indicates a change of +13.3% from what Intuitive Surgical is expected to report a year ago.
  • The consensus sales estimate of $2.61 billion for the current quarter points to a year-over-year change of +15.8%, demonstrating robust revenue growth.
  • The reported revenues of $2.87 billion in the last quarter represented a year-over-year change of +18.8%, exceeding expectations with an EPS surprise of +12.44%.
  • Intuitive Surgical has beaten consensus EPS estimates in each of the trailing four quarters, showcasing consistent outperformance.
  • The company topped consensus revenue estimates three times over the trailing four-quarter period, indicating strong fundamentals.
  • A year-over-year change of +14.8% in current fiscal year revenue and +12.2% growth in the next fiscal year further supports long-term earnings trajectory.
Risk Factors
  • Shares of Intuitive Surgical have returned -7.8% over the past month, significantly underperforming both the Zacks S&P 500 composite (-3.3%) and the Medical Instruments industry (-6.4%).
  • The stock is rated with a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market rather than outperform.
  • Intuitive Surgical is graded D on the Zacks Value Style Score, indicating that its stock is trading at a premium to its peers and is considered overvalued based on traditional and unconventional valuation metrics.
  • For the next fiscal year, the consensus earnings estimate has changed by -0.2% over the last month, signaling a slight negative revision in analyst expectations.
Bullish +75

Intuitive Surgical: The Robotic Surgery Leader Still Has Massive Growth Ahead

Intuitive Surgical (ISRG) is a market leader in robotic surgery systems, particularly known for its da Vinci surgical platforms. A recent analysis initiates the stock with a "Buy" rating and establishes a price target of $584.87, which suggests approximately 19% upside potential from current levels. The investment thesis rests on the company's robust business model characterized by recurring revenue streams from high-margin consumables used during procedures and ongoing service contracts for hospital clients. Furthermore, the analyst anticipates continued growth driven by the increasing adoption of robotic surgery techniques globally and significant opportunities for international expansion into emerging markets. The article addresses recent headwinds, noting that operating margins experienced temporary pressure due to specific factors including tariffs on imported components and the capital-intensive rollout of the newer da Vinci 5 robotic system. Despite these challenges, the company's operational resilience is highlighted, with expectations that operating margins will stabilize by 2026. The analyst acknowledges key risks such as potential long-term exposure to tariff policies and the emergence of new competitors attempting to replicate the proprietary technology, but emphasizes that Intuitive Surgical's established market dominance, history of innovation, and strong balance sheet justify its premium valuation. The content concludes with a brief author biography for Dhierin-Perkash Bechai of The Aerospace Forum, identifying his background in aerospace engineering and his specific focus on investment opportunities within the aerospace, defense, and airline sectors. While the article mentions that researching medical technology fits within an aerospace research framework due to technological overlaps, the primary focus remains on ISRG's financial performance, strategic growth drivers, and valuation metrics for investors seeking exposure to the medical device sector.

📈 Initiated as a Buy with a $584.87 target, offering 19% upside potential.

💰 Recurring revenue from consumables and services supports the robust business model.

⚠ Margins face temporary tariff headwinds but are expected to stabilize by 2026.

🚀 Growth driven by global robotics adoption and technological innovation in surgery.

⚡ Key risks include tariff exposure and emerging competition in the sector.

📈 Intuitive Surgical is being initiated with a Buy rating and a $584.87 price target, representing 19% upside potential from current levels.

💰 The company's business model is supported by robust recurring revenues derived from consumables and service contracts.

🤖 Growth expectations are anchored in continued adoption of robotic surgery systems and strategic international market expansion.

⚠️ Operating margins faced temporary headwinds due to tariff pressures and costs associated with launching the Da Vinci 5 system.

📉 Analysts anticipate that operating margins will stabilize by 2026 despite the recent temporary pressure.

⚡ Key risks identified include ongoing exposure to tariffs and the emergence of new competitors in the robotic surgery space.

🏆 Market leadership, technological innovation, and a strong balance sheet are cited as drivers for ISRG's premium valuation.

🛸 While primarily a medical technology company, the investment case is being analyzed within an aerospace and defense research framework due to overlapping technological themes.

👤 The analyst Dhierin-Perkash Bechai runs The Aerospace Forum, which specializes in investment opportunities within aerospace, defense, and airline industries.

📝 Standard disclosure notes that the author has no stock positions or compensation plans related to the companies mentioned in the report.

🚫 Seeking Alpha clarifies that it is not a licensed securities dealer or investment adviser and that past performance does not guarantee future results.

Bullish Signals
  • Initiated Buy with $584.87 target showing 19% upside.
  • Recurring consumables revenues drive robotic surgery growth.
  • Operating margins resilient and expected to stabilize in 2026.
  • Strong balance sheet supports premium valuation and innovation.
Risk Factors
  • Tariffs and Da Vinci 5 rollout pressured margins temporarily.
  • New entrants threaten dominant position in robotic surgery.
  • Ongoing tariff exposure risks future margin stability.
  • Margin compression continues despite stabilization expectations by 2026.
Bullish Signals
  • Intuitive Surgical has been initiated with a Buy rating and a $584.87 price target, reflecting significant 19% upside potential.
  • The company's business model benefits from robust recurring revenues in consumables and services, driving continued growth in robotic surgery adoption and international expansion.
  • Despite temporary margin pressure, Intuitive Surgical's operating margins remained resilient and are expected to stabilize by 2026.
  • ISRG possesses a strong balance sheet that underpins its premium valuation while maintaining market leadership and innovation.
Risk Factors
  • Margins faced temporary pressure from tariffs and the Da Vinci 5 rollout, creating short-term financial headwinds.
  • The company faces significant competition from new entrants in the robotic surgery market which could challenge its dominant position.
  • Tariff exposure remains a key risk that could impact margins if trade policies continue to tighten or expand.
  • While operating margins are expected to stabilize by 2026, this suggests current margin compression is an ongoing concern rather than a resolved issue.